The termination does not impact Medtronic’s fiscal year 2024 adjusted earnings per share guidance range that the company provided on November 21, 2023. Medtronic continues to advance its automated insulin dosing product pipeline, including a differentiated patch pump.
Related Posts
Lowe’s trims annual forecasts but quarterly profit beat lifts shares
By Savyata Mishra (Reuters) -Lowe’s Cos signaled a strong start to the fourth quarter after topping profit estimates, but followed…
Nuclear’s Second Act: Energy Stocks Set to Soar Before 2026
The world is quietly entering a new nuclear age. As electricity demand spikes from AI, EVs, and global manufacturing, countries are…
Nvidia relief won’t be enough to dispel tech-bubble angst
By Dhara Ranasinghe LONDON (Reuters) -Markets may have weathered a key Nvidia earnings test but the ability of big tech…